Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 11/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 3/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29155917 | 1.00 | MAPK8 (0.39) | MAPK8MAPK9CCNT1CDK2CDK7 | |
| SCHEMBL29326234 | 1.00 | MAPK8 (0.39) | MAPK8MAPK9CCNT1CDK2CDK7 | |
| SCHEMBL29325964 | 1.00 | MAPK8 (0.39) | MAPK8MAPK9CCNT1CDK2CDK7 | |
| SCHEMBL30684778 | 1.00 | MAPK8 (0.39) | MAPK8MAPK9CCNT1CDK2CDK7 | |
| SCHEMBL29155922 | 1.00 | MAPK8 (0.39) | MAPK8MAPK9CCNT1CDK2CDK7 | |
| SCHEMBL29325972 | 0.97 | MAPK8 (0.39) | MAPK8MAPK9CCNT1CDK2CDK7 | |
| SCHEMBL29325879 | 0.91 | IRAK4 (0.35) | MAPK8MAPK9CCNT1CDK9PTPN11 | |
| SCHEMBL29325872 | 0.91 | IRAK4 (0.35) | MAPK8MAPK9CCNT1CDK9PTPN11 | |
| SCHEMBL29325869 | 0.82 | MAPK10 (0.36) | MAPK8MAPK9CDK2CDK7CDK9 | |
| SCHEMBL29325826 | 0.82 | PDE4A (0.50) | PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | MAPK8 3960/4885MAPK9 4007/4885CCNT1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.